IL157467A0 - Method to obtain microparticles containing a h+,k+-atp-ase inhibitor - Google Patents

Method to obtain microparticles containing a h+,k+-atp-ase inhibitor

Info

Publication number
IL157467A0
IL157467A0 IL15746702A IL15746702A IL157467A0 IL 157467 A0 IL157467 A0 IL 157467A0 IL 15746702 A IL15746702 A IL 15746702A IL 15746702 A IL15746702 A IL 15746702A IL 157467 A0 IL157467 A0 IL 157467A0
Authority
IL
Israel
Prior art keywords
sup
atp
ase inhibitor
microparticles containing
obtain microparticles
Prior art date
Application number
IL15746702A
Other languages
English (en)
Original Assignee
Astrazeneca Ab Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab Astrazeneca Ab filed Critical Astrazeneca Ab Astrazeneca Ab
Publication of IL157467A0 publication Critical patent/IL157467A0/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Disintegrating Or Milling (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • General Preparation And Processing Of Foods (AREA)
IL15746702A 2001-03-09 2002-03-06 Method to obtain microparticles containing a h+,k+-atp-ase inhibitor IL157467A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE0100822A SE0100822D0 (sv) 2001-03-09 2001-03-09 Method II to obtain microparticles
PCT/SE2002/000400 WO2002072071A1 (en) 2001-03-09 2002-03-06 Method to obtain microparticles containing a h+, k+ -atp-ase inhibitor

Publications (1)

Publication Number Publication Date
IL157467A0 true IL157467A0 (en) 2004-03-28

Family

ID=20283293

Family Applications (1)

Application Number Title Priority Date Filing Date
IL15746702A IL157467A0 (en) 2001-03-09 2002-03-06 Method to obtain microparticles containing a h+,k+-atp-ase inhibitor

Country Status (22)

Country Link
US (2) US20040101565A1 (de)
EP (1) EP1370243B1 (de)
JP (1) JP2004522796A (de)
KR (1) KR20030081506A (de)
CN (1) CN1507343A (de)
AT (1) ATE400253T1 (de)
AU (1) AU2002235101B8 (de)
BR (1) BR0207827A (de)
CA (1) CA2440163A1 (de)
DE (1) DE60227488D1 (de)
DK (1) DK1370243T3 (de)
ES (1) ES2307722T3 (de)
HK (1) HK1059896A1 (de)
IL (1) IL157467A0 (de)
MX (1) MXPA03007887A (de)
NO (1) NO20033966L (de)
NZ (1) NZ527997A (de)
PT (1) PT1370243E (de)
SE (1) SE0100822D0 (de)
SI (1) SI1370243T1 (de)
WO (1) WO2002072071A1 (de)
ZA (1) ZA200306614B (de)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE0100823D0 (sv) * 2001-03-09 2001-03-09 Astrazeneca Ab Method I to obtain microparticles
US20060159756A1 (en) * 1999-09-10 2006-07-20 Brita Sjoblom Method to obtain microparticles containing an H+,K+-ATP-ASE inhibitor
US9700866B2 (en) 2000-12-22 2017-07-11 Baxter International Inc. Surfactant systems for delivery of organic compounds
US8067032B2 (en) 2000-12-22 2011-11-29 Baxter International Inc. Method for preparing submicron particles of antineoplastic agents
SE0100822D0 (sv) * 2001-03-09 2001-03-09 Astrazeneca Ab Method II to obtain microparticles
SE0100824D0 (sv) * 2001-03-09 2001-03-09 Astrazeneca Ab Method III to obtain microparticles
BR0212833A (pt) 2001-09-26 2004-10-13 Baxter Int Preparação de nanopartìculas de tamanho submìcron através de dispersão e de remoção de solvente ou de fase lìquida
US20060003012A9 (en) 2001-09-26 2006-01-05 Sean Brynjelsen Preparation of submicron solid particle suspensions by sonication of multiphase systems
WO2004080439A1 (ja) 2003-03-12 2004-09-23 Takeda Pharmaceutical Company Limited 高濃度に活性成分を球形核に付着させた医薬組成物
DE10325989A1 (de) * 2003-06-07 2005-01-05 Glatt Gmbh Verfahren zur Herstellung von und daraus resultierende Mikropellets sowie deren Verwendung
US20050181052A1 (en) * 2004-02-17 2005-08-18 Patel Satishkumar A. Lansoprazole microtablets
WO2007095376A2 (en) * 2006-02-15 2007-08-23 Kennametal Inc. Method and apparatus for coating particulates utilizing physical vapor deposition
CH698658B1 (de) * 2006-04-24 2009-09-30 Mepha Ag Orale pharmazeutische Formulierung mit schneller Freisetzung für Pyridylmethylsulfinyl-Benzimidazole.
US20090087569A1 (en) * 2007-09-27 2009-04-02 Fenchem Enterprises Ltd. Methods for Preparing Highly Stable Hyaluronic Acid
IT1401284B1 (it) * 2010-08-06 2013-07-18 Valpharma S P A Nuove formulazioni farmaceutiche idonee per la somministrazione orale di esomeprazolo magnesio diidrato, in forma di compresse mups (multi unit pellets system).
US10736855B2 (en) 2016-02-25 2020-08-11 Dexcel Pharma Technologies Ltd. Compositions comprising proton pump inhibitors
US10076494B2 (en) 2016-06-16 2018-09-18 Dexcel Pharma Technologies Ltd. Stable orally disintegrating pharmaceutical compositions
US20230058473A1 (en) * 2020-01-27 2023-02-23 Towa Pharmaceutical Co., Ltd. Esomeprazole oral preparation and method for producing the same

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3565475D1 (en) * 1984-04-07 1988-11-17 Bayer Ag Process and apparatus for the production of granules
IL75400A (en) * 1984-06-16 1988-10-31 Byk Gulden Lomberg Chem Fab Dialkoxypyridine methyl(sulfinyl or sulfonyl)benzimidazoles,processes for the preparation thereof and pharmaceutical compositions containing the same
GB2189698A (en) * 1986-04-30 1987-11-04 Haessle Ab Coated omeprazole tablets
DE3909455A1 (de) * 1989-03-22 1990-09-27 Hoechst Ag Verfahren zur herstellung von wasserdispergierbaren granulaten
CZ289804B6 (cs) * 1994-07-08 2002-04-17 Astrazeneca Ab Multijednotková tabletovaná dávková forma I
FR2725623A1 (fr) * 1994-10-18 1996-04-19 Flamel Tech Sa Microcapsules medicamenteuses et/ou nutritionnelles pour administration per os
DE19613395A1 (de) * 1996-04-03 1997-10-09 Basf Ag Granulate hygroskopischer, wasserlöslicher Produkte
DE19733094A1 (de) * 1997-07-31 1999-02-04 Merck Patent Gmbh Formulierung auf der Basis von Ascorbinsäure mit verbesserter Farbstabilität
US6861069B2 (en) * 1997-10-15 2005-03-01 Merck Gesellschaft Mit Beschraenkter Haftung Production of a directly compressible tabletting aid
US6174548B1 (en) * 1998-08-28 2001-01-16 Andrx Pharmaceuticals, Inc. Omeprazole formulation
AU751066B2 (en) * 1997-12-08 2002-08-08 Nycomed Gmbh Novel administration form comprising an acid-labile active compound
US20060159756A1 (en) * 1999-09-10 2006-07-20 Brita Sjoblom Method to obtain microparticles containing an H+,K+-ATP-ASE inhibitor
SE0100823D0 (sv) * 2001-03-09 2001-03-09 Astrazeneca Ab Method I to obtain microparticles
SE9903236D0 (sv) * 1999-09-10 1999-09-10 Astra Ab Method to obtain microparticles
SE0100822D0 (sv) * 2001-03-09 2001-03-09 Astrazeneca Ab Method II to obtain microparticles
SE0100824D0 (sv) * 2001-03-09 2001-03-09 Astrazeneca Ab Method III to obtain microparticles

Also Published As

Publication number Publication date
US20080175917A1 (en) 2008-07-24
DK1370243T3 (da) 2008-10-13
DE60227488D1 (de) 2008-08-21
HK1059896A1 (en) 2004-07-23
ZA200306614B (en) 2004-11-25
WO2002072071A1 (en) 2002-09-19
EP1370243B1 (de) 2008-07-09
NO20033966L (no) 2003-11-03
JP2004522796A (ja) 2004-07-29
CN1507343A (zh) 2004-06-23
ES2307722T3 (es) 2008-12-01
SE0100822D0 (sv) 2001-03-09
KR20030081506A (ko) 2003-10-17
PT1370243E (pt) 2008-09-16
MXPA03007887A (es) 2003-12-04
CA2440163A1 (en) 2002-09-19
SI1370243T1 (sl) 2008-12-31
US20040101565A1 (en) 2004-05-27
NO20033966D0 (no) 2003-09-08
AU2002235101B2 (en) 2006-07-13
EP1370243A1 (de) 2003-12-17
AU2002235101B8 (en) 2006-08-31
NZ527997A (en) 2005-02-25
BR0207827A (pt) 2004-03-02
ATE400253T1 (de) 2008-07-15

Similar Documents

Publication Publication Date Title
HK1059896A1 (en) Method to obtain microparticles containing a h+, k+ -atp-ase inhibitor
DE69936386D1 (de) Sprühgetrocknete proteinformulierungen
AU587863B2 (en) Vitamin-containing granules and production thereof
TNSN01108A1 (en) Oxygenated esters of 4-iodo phenylamino benzhydroxamic acids
WO2004012700A3 (en) Dosage form comprising high dose high soluble active ingredient as modified release and low dose active ingredient as immediate release
AU7119500A (en) Nanoparticulate compositions comprising amorphous cyclosporine and methods of making and using such compositions
AU2623095A (en) Piperazine derivatives as 5ht1a antagonists
EP0931788A3 (de) Metalloproteinase-Inhibitoren
WO2003032953A1 (fr) Granules contenant un agent chimique instable en milieu acide, en concentration elevee
HK1044349B (zh) 含有1，1，1，3，3-五氟丁烷的組合物及此種組合物的用途
MX250472B (es) Granulos o polvo para la produccion de agentes de recubrimiento y aglutinantes para formas farmaceuticas.
CO5580776A2 (es) Formulacion farmaceutica estable en solucion de oxaliplatino
WO2002049590A3 (en) Antiperspirant products
BR0206164A (pt) Partìculas cristalinas de oxalato de escitalopram, método para a produção de partìculas cristalinas de oxalato de escitalopram, e, forma de dosagem unitária sólida
WO2002007669A3 (en) Phospholipid derivatives of valproic acid and mixtures thereof
NO20033967D0 (no) Fremgangsmåte for fremstilling av mikropartikler som inneholder metoprolol
CA2348836A1 (en) Feed for livestock
EA200300235A1 (ru) Способ получения гранул метионина
IL162314A (en) Pyridine-2,4-dicarboxylic acid diamides and pyrimidine-4,6-dicarboxylic acid diamides, processes for their preparation, pharmaceutical compositions comprising them and uses thereof
AP2000001837A0 (en) Pharmaceutical compositions containing micronized bicyclic drugs.
EP1186292A3 (de) Feste Zubereitungen mit einer Multi-Kern Struktur
AU2003267551A1 (en) Thieno-pyrrole compounds as antagonists of gonadotropin releasing hormone
AU2566101A (en) Compounds and methods for the treatment of pain
CA2355720A1 (en) New substituted 3-phenoxy and 3-phenylalkyloxy-2-phenyl-propylamines
ATE275401T1 (de) Herstellung von inogatran-agglomeraten und die verbindung inogatran-anhydrid